Skip to main navigation Skip to search Skip to main content

A Double-blind, Randomized, Psychoactive Placebo-controlled, Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction

Project: Research

Project Details

StatusFinished
Effective start/end date12/20/18 → 12/20/20

Funding

  • Janssen Research and Development LLC: $14,875.00